Heterogeneity in randomized controlled trials of long chain (fish) omega-3 fatty acids in restenosis, secondary prevention and ventricular arrhythmias.
Randomized controlled trials of marine omega-3 fatty acid supplementation in relation to coronary heart disease (CHD) have inconsistent outcomes, yet public health messages are uniformly positive. Originally, fish were seen as a low saturated fat protein source, and later as a valuable source of ome...
| Publicado en: | Journal of the American College of Nutrition Vol. 27; no. 3; pp. 367 - 379 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | research review Journal Article |
| Publicado: |
Taylor & Francis Ltd
Jun2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105627114&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105627114 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 07315724 2QK8 jtl: Journal of the American College of Nutrition issn: 07315724 maglogo: Y pubinfo: dt: Jun2008 vid: 27 iid: 3 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 105627114 NLM18838524 2010158657 10.1080/07315724.2008.10719713 NLM18838524 105627114 ppf: 367 ppct: 12 formats: tig: atl: Heterogeneity in randomized controlled trials of long chain (fish) omega-3 fatty acids in restenosis, secondary prevention and ventricular arrhythmias. aug: au: Jenkins DJ Josse AR Dorian P Burr ML LaBelle Trangmar R Kendall CW Cunnane SC Jenkins, David J A Josse, Andrea R Dorian, Paul Burr, Michael L LaBelle Trangmar, Roxanne Kendall, Cyril W C Cunnane, Stephen C affil: Clinical Nutrition & Risk Factor Modification Center, St. Michael's Hospital, Toronto, Ontario, Canada sug: subj: Arrhythmia Prevention and Control Coronary Disease Diet Therapy Fish Oils Therapeutic Use Clinical Trials Coronary Disease Coronary Disease Complications Coronary Restenosis Prevention and Control Dietary Supplements Fish Oils Adverse Effects Fish Oils Pharmacodynamics Male Recurrence Prevention and Control Risk Factors Male ab: Randomized controlled trials of marine omega-3 fatty acid supplementation in relation to coronary heart disease (CHD) have inconsistent outcomes, yet public health messages are uniformly positive. Originally, fish were seen as a low saturated fat protein source, and later as a valuable source of omega-3 fatty acids. Early trials indicated that increased fish oil consumption prevented restenosis after coronary angioplasty. Later trials demonstrated that fish oils prolonged life post myocardial infarction (MI). Currently, the potential antiarrhythmic effects of fish derived omega-3 fatty acids are seen as the primary reason for cardiac benefits, as suggested by one trial with compliant subjects with implantable cardioverter defibrillators (ICDs), and sudden death reduction in a post MI trial. However, the earlier benefits of EPA and DHA on restenosis have only been confirmed in a subgroup in a recent meta-analysis. Newer data indicate that fish oils may increase CHD events in men with angina. Furthermore, in two of three trials in patients with ICDs and a history of ventricular arrhythmias, fish oils showed no significant benefit or even increased the risk of appropriate ICD discharge. Certain groups of individuals may benefit from long-chain omega-3 fatty acids while others, including men with angina and some individuals with a history of ventricular arrhythmia, may not. Due to significant heterogeneity in the response to fish oils, further studies are required before making widespread recommendations for all groups to increase consumption of fish and fish oil. pubtype: Academic Journal doctype: research review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|